• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by 10x Genomics Inc.

    11/5/24 6:07:26 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TXG alert in real time by email
    SC 13G 1 txg1028240sc13g.htm

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     ________________ 

      

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. n/a)*

     

     

    10x Genomics, Inc.
    (Name of Issuer)
     
    Class A common stock, par value $0.00001 per share
    (Title of Class of Securities)
     
    88025U109
    (CUSIP Number)
     
    September 30, 2024
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒       Rule 13d-1(b)

     

    ☐       Rule 13d-1(c)

     

    ☐       Rule 13d-1(d)

     

     

                                                                     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     Page 1 of 9 
     

     

    CUSIP No. 88025U109                 13G  

     

    1.

    NAMES OF REPORTING PERSONS

     

    Sumitomo Mitsui Trust Group, Inc.  (“SMTG”)

      

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
       

    (b) ☐

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Japan

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

    0

     

    6.

    SHARED VOTING POWER

    6,373,212

     

    7.

    SOLE DISPOSITIVE POWER

    0

     

    8.

    SHARED DISPOSITIVE POWER

    6,373,212

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,373,212

     

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.98%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    HC, FI

     

     Page 2 of 9 
     

     

    CUSIP No. 88025U109 13G  

     

    1.

    NAMES OF REPORTING PERSONS

     

    Nikko Asset Management Co., Ltd. (“NAM”)

        

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
       

    (b) ☐

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Japan

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

    0

     

    6.

    SHARED VOTING POWER

    6,373,212

     

    7.

    SOLE DISPOSITIVE POWER

    0

     

    8.

    SHARED DISPOSITIVE POWER

    6,373,212

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,373,212

     

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.98%

    12.

    TYPE OF REPORTING PERSON

     

    IA, HC, FI

     

     

     Page 3 of 9 
     

     

    Item 1(a).Name of Issuer:

     

    10x Genomics, Inc.

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    6230 Stoneridge Mall Road, Pleasanton, California 94588

     

    Item 2(a).Name of Person Filing:

     

    Sumitomo Mitsui Trust Group, Inc.

     

    Nikko Asset Management Co., Ltd.

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    SMTG: 1-4-1 Marunouchi, Chiyoda-ku, Tokyo 100-8233, Japan

     

    NAM: Midtown Tower, 9-7-1 Akasaka, Minato-ku, Tokyo 107-6242, Japan

     

    Item 2(c).Citizenship:

     

    SMTG: Japan

     

    NAM: Japan

     

    Item 2(d).Title of Class of Securities:

     

    Class A common stock, par value $0.00001 per share

     

    Item 2(e).CUSIP Number:

     

    88025U109

     

     Page 4 of 9 
     

     

    Item 3.If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    SMTG:

     

    (a) ☐  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
         
    (b) ☐  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) ☐  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d) ☐  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) ☐  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ☐  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ☒  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ☐  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ☐  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ☒  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) ☐  Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Parent Holding Company

     

    NAM:

     

    (a) ☐  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
         
    (b) ☐  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) ☐  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d) ☐  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) ☒  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ☐  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ☒  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ☐  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ☐  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ☒  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) ☐  Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

     Page 5 of 9 
     

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Investment Adviser, Parent Holding Company

     

    Item 4.Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of issuer identified in Item 1.

     

    SMTG:    
         
      (a)   Amount beneficially owned: 6,373,212
           
      (b)   Percent of class: 5.98%
           
      (c)   Number of shares as to which such person has:
           
      (i)   Sole power to vote or to direct the vote: 0
           
      (ii)   Shared power to vote or to direct the vote: 6,373,212
           
      (iii)   Sole power to dispose or to direct the disposition of: 0
           
      (iv)  

    Shared power to dispose or to direct the disposition of: 6,373,212

           
    NAM:    
         
      (a)   Amount beneficially owned: 6,373,212
           
      (b)   Percent of class: 5.98%
           
      (c)   Number of shares as to which such person has:
           
      (i)   Sole power to vote or to direct the vote: 0
           
      (ii)   Shared power to vote or to direct the vote: 6,373,212
           
      (iii)   Sole power to dispose or to direct the disposition of: 0
           
      (iv)   Shared power to dispose or to direct the disposition of: 6,373,212

     

     Page 6 of 9 
     

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    See Exhibit A.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    See Exhibit A.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 9 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 5, 2024

     

      Sumitomo Mitsui Trust Group, Inc.
      (Company)
       
      /s/ Hideaki Takamiya
     

    (Signature)

     

    Hideaki Takamiya / Senior Manager of Risk Management Dept 

      (Name/Title)
       
      Nikko Asset Management Co.,Ltd 
      (Company)
       
      /s/ Atsushi Ohya
     

    (Signature)

     

    Atsushi Ohya / Head of Business Regulatory Compliance 

      (Name/Title)

     

     Page 8 of 9 
     

     

    Exhibit A

     

    Pursuant to the instructions in Item 6 and Item 7 of Schedule 13G, the securities being reported on by each of SMTG and NAM, as parent holding companies, are owned, or may be deemed to be beneficially owned, by their subsidiary Nikko Asset Management Americas, Inc., which is classified as an investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    In addition, SMTH has changed the company name to SMTG as of October 1, 2024.

     

     

    Page 9 of 9

     

     

     

    Get the next $TXG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TXG

    DatePrice TargetRatingAnalyst
    2/13/2025$25.00 → $12.00Outperform → Market Perform
    Leerink Partners
    9/3/2024$35.00Outperform
    Leerink Partners
    7/22/2024$24.00Hold → Buy
    Jefferies
    7/18/2024$40.00 → $20.00Overweight → Neutral
    JP Morgan
    7/10/2024$55.00 → $25.00Buy → Hold
    Deutsche Bank
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    6/25/2024Buy → Neutral
    Guggenheim
    6/3/2024$24.00Hold
    Jefferies
    More analyst ratings

    $TXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Saxonov Serge was granted 171,428 shares, increasing direct ownership by 19% to 1,092,968 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      3/19/25 5:35:44 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Officer Hindson Benjamin J. was granted 120,535 shares, increasing direct ownership by 36% to 455,859 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      3/19/25 5:35:12 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Financial Officer Taich Adam was granted 335,632 shares (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      3/19/25 5:34:38 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 10x Genomics Reports First Quarter 2025 Financial Results

      PLEASANTON, Calif., May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025. Recent Updates Revenue was $154.9 million for the first quarter. Excluding $16.8 million related to a patent litigation settlement, revenue was $138.1 million, a 2% decrease from the corresponding period of 2024, primarily driven by a significant decrease in instrument revenue.Ended the first quarter with cash and cash equivalents and marketable securities of $426.9 million. As

      5/8/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference

      PLEASANTON, Calif., April 30, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference on Tuesday, May 13, at 11:20 a.m. Pacific Time. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event. About 10x Genomics

      4/30/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025

      PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 8, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

      4/14/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    SEC Filings

    See more
    • 10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

      8-K - 10x Genomics, Inc. (0001770787) (Filer)

      5/8/25 4:05:10 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.

      SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      5/7/25 10:55:48 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.

      SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      5/7/25 10:40:41 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • 10x Genomics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded 10x Genomics from Outperform to Market Perform and set a new price target of $12.00 from $25.00 previously

      2/13/25 7:11:34 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Leerink Partners initiated coverage on 10x Genomics with a new price target

      Leerink Partners initiated coverage of 10x Genomics with a rating of Outperform and set a new price target of $35.00

      9/3/24 8:15:17 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics upgraded by Jefferies with a new price target

      Jefferies upgraded 10x Genomics from Hold to Buy and set a new price target of $24.00

      7/22/24 8:21:12 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by 10x Genomics Inc.

      SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

      11/8/24 2:46:37 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by 10x Genomics Inc.

      SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

      11/5/24 6:07:26 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by 10x Genomics Inc.

      SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      10/4/24 2:14:32 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mateo Alan bought $445,572 worth of shares (40,000 units at $11.14), increasing direct ownership by 184% to 61,691 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      2/25/25 5:22:04 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Financials

    Live finance-specific insights

    See more
    • 10x Genomics Reports First Quarter 2025 Financial Results

      PLEASANTON, Calif., May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025. Recent Updates Revenue was $154.9 million for the first quarter. Excluding $16.8 million related to a patent litigation settlement, revenue was $138.1 million, a 2% decrease from the corresponding period of 2024, primarily driven by a significant decrease in instrument revenue.Ended the first quarter with cash and cash equivalents and marketable securities of $426.9 million. As

      5/8/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025

      PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 8, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

      4/14/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

      PLEASANTON, Calif., Feb. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for 2025. Recent Updates Revenue was $165.0 million for the fourth quarter and $610.8 million for the full year of 2024, representing 10% and 1% decreases over the corresponding periods of 2023.In collaboration with the Chan Zuckerberg Initiative (CZI) and Ultima Genomics, launched the Billion Cells Project, an effort to generate an unpre

      2/12/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Leadership Updates

    Live Leadership Updates

    See more
    • 10x Genomics Announces Senior Leadership Changes

      PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to join a private company.Adam Taich has been appointed Chief Financial Officer

      8/8/24 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Fanatics Announces Appointment of Lydia Jett and Jonathan Mildenhall to Board of Directors

      Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform Separately, Fanatics releases its first environmental, social and governance (ESG) report Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising an

      5/5/22 8:30:00 AM ET
      $CPNG
      $GH
      $OZON
      $TXG
      Catalog/Specialty Distribution
      Consumer Discretionary
      Medical Specialities
      Health Care
    • ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer

      Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today. Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the boar

      1/10/22 8:00:00 AM ET
      $RARE
      $TXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials